ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

It's Never too Early to Test: Frequent Anti-A2 Titer Monitoring in Blood Group B Patients is Necessary.

S. Radomski, S. Rosen-Bronson, B. Diedrich, A. Langeberg, D. Li, M. Awwad, M. Grafals, M. Cooper, A. Gilbert.

Medstar Georgetown Transplant Institute, Washington, DC

Meeting: 2017 American Transplant Congress

Abstract number: D305

Keywords: Allocation, Antibodies, Kidney transplantation

Session Information

Session Name: Poster Session D: Non-Organ Specific: Economics, Public Policy, Allocation, Ethics

Session Type: Poster Session

Date: Tuesday, May 2, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Introduction:

With the implementation of the new Kidney Allocation System (KAS), deceased donor transplants from blood group A2 donors can now be implanted into blood group B recipients. However, the safety of this depends on low anti-A2 titer levels in the recipient. There is a lack of data as to the stability of these titers over time and therefore proper frequency of testing is unknown. This has limited the broad implementation of A2 to B transplants.

Methods:

From a single center's B waitlist and previous 2-year transplant record, blood group B patients were retrospectively identified who had at least two anti-A2 titer measurements. Anti-A2 titer values were collected along with information from the medical record related to possible sensitizing events. In order to account for the inherent imprecision of testing, a significant change in titer levels was defined as > 4-fold difference between measurements.

Results:

The sample included 48 adults (58% male; age 56 + 11 years). Average time between measurements was 13.31 + 6 months. Using the aforementioned criteria 35% (n=17) of patients had significant titer changes. Six patients had a significant decrease in titers, one of which was began immunosuppression and another received a blood transfusion between titers. The remaining 11 patients had a significant increase in titer levels. Between titers 4 underwent systemic antibiotic therapy (a marker of bacteremia) and 2 began hemodialysis, but the remaining 8 had no identifiable sensitizing events. Of the 31 patients with multiple titers that did not change significantly, 2 received a blood transfusion, 1 became pregnant, and 2 were treated with systemic antibiotics between measurements.Conclusion:

Over one third of anti-A2 titers show significant variability within 1 year of measurement. Careful medical history taking for hypothesized sensitizing events is not adequate to predict significant changes in titer levels. Frequent testing of anti-A2 titers is required to maintain adequate safety for patients listed for A2 to B transplants.

CITATION INFORMATION: Radomski S, Rosen-Bronson S, Diedrich B, Langeberg A, Li D, Awwad M, Grafals M, Cooper M, Gilbert A. It's Never too Early to Test: Frequent Anti-A2 Titer Monitoring in Blood Group B Patients is Necessary. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Radomski S, Rosen-Bronson S, Diedrich B, Langeberg A, Li D, Awwad M, Grafals M, Cooper M, Gilbert A. It's Never too Early to Test: Frequent Anti-A2 Titer Monitoring in Blood Group B Patients is Necessary. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/its-never-too-early-to-test-frequent-anti-a2-titer-monitoring-in-blood-group-b-patients-is-necessary/. Accessed May 12, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences